Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Metagenomi, Inc. Common Stock

Company price
0.6567 USD -0.02 ( 3.43%)
Last update at 2026-11-17T17:30:00Z
VOLUME
140883
Market Cap
43.82M

Momentum Score

…

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.61
Low
0.74
High
52 Week Price Range
1.13
Low
3.95
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.68
Dividend Yield
-
Revenue TTM
13.56M
Revenue Per Share
0.36
Gross Profit TTM
-75.03M
Debt / Equity
0.26
ROE
-60.61%
Net Debt
-1.06M
ROCE
-44.37%
Diluted EPS TTM
-2.45

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Income before tax -87.93M -83.57M -60.23M -41.02M -21.44M
Net income -87.87M -78.06M -68.25M -43.59M -21.44M
Selling general administrative 26.79M 32.02M 28.84M 18.70M 9.71M
Gross profit 19.89M 52.30M - - -
Reconciled depreciation 5.32M 5.41M 4.21M 1.73M 0.39M
Ebit -87.93M -83.57M - - -
Ebitda -82.61M -78.16M - - -
Depreciation and amortization 5.32M 5.41M - - -
Operating income -96.01M -88.90M -78.49M -44.64M -23.95M
Other operating expenses 121.22M 141.20M - - -
Interest expense - - 0.00M 0.10M 0.30M
Tax provision -0.06M -5.51M 8.03M 2.57M 0.00M
Interest income 9.47M 14.72M 15.47M 3.42M 0.04M
Net interest income 9.47M 14.72M 15.47M 3.32M -0.26M
Income tax expense -0.06M -5.51M - - -
Total revenue 25.21M 52.30M 44.76M 17.20M 0.24M
Total operating expenses 115.91M 141.20M 123.25M 61.84M 24.19M
Cost of revenue 5.32M 5.41M - - -
Total other income expense net 8.09M 5.33M 2.80M 0.29M 2.76M
Net income from continuing ops -87.87M -78.06M -68.25M -43.59M -21.44M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total assets 221.10M 324.60M 364.84M 414.49M 141.99M
Other current assets 4.43M 8.40M 4.64M 3.49M 0.27M
Total liab 62.51M 89.74M 500.43M 488.91M 174.54M
Total stockholder equity 158.60M 234.86M -135.58M -74.43M -32.54M
Other current liab 6.72M 8.42M - - -
Common stock 0.00M 0.00M - - -
Capital stock 0.00M 0.00M 9.46M 2.54M 0.57M
Retained earnings -310.87M -223.00M -144.94M -76.69M -33.10M
Cash 41.72M 27.39M 140.60M 184.44M 39.30M
Total current liabilities 22.93M 37.31M 68.86M 48.54M 25.17M
Current deferred revenue 8.70M 22.76M - - -
Net debt -1.06M 18.39M - - -
Short term debt 6.03M 5.59M - - -
Short long term debt total 40.66M 45.78M - - -
Other stockholder equity 469.20M 457.15M - - -
Total current assets 165.54M 257.96M 278.27M 366.90M 108.92M
Long term investments 2.15M 3.45M 10.68M 7.81M 6.42M
Short term investments 119.08M 220.92M 130.58M 177.69M 68.86M
Net receivables 0.30M 1.26M 2.45M 0.00M -
Long term debt - - - - 30.28M
Accounts payable 1.49M 0.53M 1.79M 2.01M 1.35M
Accumulated other comprehensive income 0.26M 0.71M - - -
Non currrent assets other 6.03M 5.54M 5.25M 6.07M 4.10M
Non current assets total 55.56M 66.64M 86.57M 47.59M 33.08M
Capital lease obligations 40.66M 45.78M 48.23M 18.57M 18.65M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Investments 104.07M -88.16M 45.73M -122.20M -74.32M
Total cashflows from investing activities 103.53M -88.16M - - -
Total cash from financing activities -0.36M 84.01M 1.01M 239.59M 39.92M
Net income -87.87M -78.06M -68.25M -43.59M -21.44M
Change in cash 14.28M -113.22M -44.66M 147.12M -10.14M
Begin period cash flow 32.63M 145.85M 190.51M 43.40M 53.53M
End period cash flow 46.91M 32.63M 145.85M 190.51M 43.40M
Total cash from operating activities -88.89M -109.07M -91.41M 29.72M 24.26M
Issuance of capital stock 0.00M 84.01M 4.29M 239.59M 9.95M
Depreciation 5.32M 5.41M 4.21M 1.73M 0.39M
Other cashflows from investing activities 3.00M - - - -
Change to account receivables 0.95M 1.19M -2.45M 0.00M -
Other cashflows from financing activities -0.56M - - - -
Capital expenditures 0.57M 3.11M 9.81M 13.98M 2.90M
Change in working capital -22.09M -59.67M -26.43M 69.49M 46.26M
Stock based compensation 11.85M 16.20M 6.92M 1.96M 0.38M
Other non cash items 3.90M 7.04M 3.46M 1.08M 1.24M
Free cash flow -89.47M -112.19M -101.22M 15.75M 21.35M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
MGX
Metagenomi, Inc. Common Stock
-0.02
3.43%
0.66 - - 3.23 0.40 0.71
NVO
Novo Nordisk A/S
-0.80
1.91%
40.80 41.58 31.15 2.13 32.99 2.11
VRTX
Vertex Pharmaceuticals Inc
-2.08
0.39%
535.71 30.22 24.27 10.36 6.50 9.99
REGN
Regeneron Pharmaceuticals Inc
9.09
0.95%
961.49 29.07 20.12 7.57 3.82 6.95
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38

Profile*

Metagenomi, Inc. Common Stock

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.

5959 Horton Street, EmeryVille, CA, United States, 94608

510 871 4880

113

Name Title Year Born
Dr. Brian Charles Thomas Ph.D. Co-Founder, CEO & Chairman of the Board 1969
Dr. Jian Irish M.B.A., Ph.D. President, COO & Director 1964
Dr. Sarah B. Noonberg M.D., Ph.D. Chief Medical Officer 1968
Dr. Jak Knowles M.D. Co-Founder & Member of Scientific Advisory Board NA
Ms. Pamela M. Wapnick M.B.A. Chief Financial Officer 1966
Dr. Luis G. Borges Ph.D. Chief Scientific Officer 1962
Mr. Matthew L. Wein J.D. Vice President of Corporate Legal, Compliance & Corporate Secretary 1971
Dr. Alan Brooks Ph.D. Senior Vice President of Preclinical 1966
Dr. Christopher Brown Head of Discovery 1989
Dr. Jian Irish M.B.A., Ph.D. CEO, President & Director 1964

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…